# Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.

> **NCT04797702** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 67 (estimated)

## Conditions studied

- Relapsed or Metastatic Non-small Cell Lung Cancer

## Interventions

- **COMBINATION_PRODUCT:** Glumetinib combined with Toripalimab

## Key facts

- **NCT ID:** NCT04797702
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-15
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-02-26
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2021-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797702, "Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04797702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*